NEW RESEARCH IN PARKINSON'S DISEASE
The key to a breakthrough in Parkinson's Disease could lie in
using the brain's own dormant cells, according to New Zealand
professor of anatomy Richard Faull.
Professor Faull has told a recent Parkinson's Disease conference
in Auckland that while transplanting cells from aborted fetuses into
those with parkinsonism has shown almost miraculous results in some
cases, there are a lot of ethical problems with using terminated
Instead, professor Faull believes a breakthrough in the treatment
of Parkinson's disease lies in the possibility of getting an
individual's own primitive brain cells to start producing the brain
chemical, dopamine, or to stop those cells from dying, or getting the
cells to live longer.
People with Parkinson's disease have a shortage of dopamine which
leads to incorrect messages being sent to the movement control centre
in the brain, causing tremors, stiffness and slow movement.
Faull said in future it may be possible to culture the brain's own
immature cells and turn them into dopamine producing cells and then
transfer them back to the patient.
Currently the main treatment for Parkinson's disease is the use of
the drug levodopa which is converted into dopamine in the brain.
However, the problem with this drug and similar therapies is that
they lose their effectiveness over time.
Faull said there had been a recent resurgence in the use of brain
surgery to control symptoms of Parkinson's disease, with the
development of more advanced scanning technology. These operations
were highly successful in certain groups of patients.
The operations known as thalamotomy and pallidotomy involve the
use of a probe to destroy a tiny part of the brain which is involved
in the symptoms of Parkinson's disease.
Another operation has been developed which involves use of a
device, similar to a pacemaker, to stimulate the same area of the
brain, which is likely become more widespread for some groups of
patients in future.
The mechanical device is inserted into the collar bone with a wire
attached to the deep part of the brain responsible for sending
incorrect messages to the movement centre. The patient can use a
magnet rubbed over the device to turn it on and off, and to stimulate
the area when necessary.
So far, professor Faull said the transplant of fetal cells into
the brain to start producing dopamine had shown a lot of promise.
"These embryonic cells will actually grow and survive and will
produce new connections and they will produce chemicals but they have
to be very young immature cells."
However, he has outlined several reasons why this is unlikely to
become an accepted medical treatment at this stage; including ethical
problems, poor cell survival, availability of abortion tissue and
variable evaluation methods.
Parkinson's disease effects about one in 10,000 people and while
the average onset is over the age of 55, the disease is beginning to
show in younger people. The reason for this is unknown.
Faull believes the best hope of an effective treatment in
Parkinson's Disease is to prevent the dopamine cells from dying or
finding a way to turn on the brain's own immature cells which do
nothing and make them produce dopamine.
Professor Faull's own research at Auckland Medical School has
shown the ability to prevent dopamine cells from dying in rats
treated with growth factors. However, it will be several years before
the trials of the growth factors can begin on humans.
Another possibility for the future is taking the brain's dormant,
immature cells and culturing them in the laboratory by instructing
them with genetic information to make dopamine and then transferring
them back to the patient. Professor Faull said this technology has
the potential to work for several medical conditions.
Copyright © 2009 The Online Services Group (N.Z)